Ran Geng
Principal·OrbiMed
San Francisco, CA, USA
Ran Geng joined OrbiMed in 2021 and is a Principal on the Private Equity team. Before OrbiMed, she was Vice President in biotech venture investments at Matrix Partners China and earlier consulted at ZS Associates on M&A and clinical-development strategy for Roche/Genentech, Gilead, and Novartis. Forbes reported that she had led investments including ArriVent Biopharma, Nikang Therapeutics, and Senti Biosciences.
See the rest of Ran Geng's profile.
Deal history, investment focus, outreach angles and the rest of the background. One email, no password — we send a link and you land right back here.